ERBB2 and neoplasm: To enhance the anti-tumor activity of T cells, the researchers synthesized a multivalent antibody to retarget EVs, which express monoclonal antibodies specific for T-cell CD3, and cancer cell-associated epidermal growth factor receptor (EGFR) (Cheng et al., 2018) or human epidermal growth factor receptor 2 (HER2) (Shi et al., 2020).